Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows

Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows

The present invention relates to methods for treating infectious diseases in animals by initiating qualitative and quantitative changes in the phagocytic cells of said animals. This activation occurs by the administration of a phagocytic-cell activating agent, such as immunomodulators; cytokines suc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: DALEY, MICHAEL JOSEPH
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator DALEY, MICHAEL JOSEPH
description The present invention relates to methods for treating infectious diseases in animals by initiating qualitative and quantitative changes in the phagocytic cells of said animals. This activation occurs by the administration of a phagocytic-cell activating agent, such as immunomodulators; cytokines such as interleukins (interleukin -1, 2, 3, 4, 5, 6 and 7), interferons and colony stimulating factors; antimicrobials such as mucolytic enzymes, lysozyme, lysostaphin; complement and its components; chemotractants such as lipopolysaccharide and zymosan activated cow sera. The appropriate activation of the phagocytic cells in the animal for effective therapy requires not only an increase in the total number of cells which phagocytose cell particles, but also an increase in the number of particles phagocytosed per cell, intracellular killing. Thus, the present invention also relates to a method for measuring the efficiency of phagocytic-activating agents to predict and monitor appropriate therapy.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP0405315A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP0405315A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP0405315A23</originalsourceid><addsrcrecordid>eNqNjTEOgkAQRWksjHqHuQAJgjR2xmA0oSBRazMZZ2ET2Nmwi4YreGpX5QBW_xfv_T-PXlfHIAoQbIO10Og5RvL6gV6bGrBm42ELZXUG6eFUximoUHzD0KEZVGCHflro-K4Ju4_xZXr-jTiPthlbISEaHGAQQmijOByJCQ1Inm4ZzRS2jldTLiI4FJf9MWYrN3YWiQ37W1ElmyTP1vkuzf5A3qxfSxo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows</title><source>esp@cenet</source><creator>DALEY, MICHAEL JOSEPH</creator><creatorcontrib>DALEY, MICHAEL JOSEPH</creatorcontrib><description>The present invention relates to methods for treating infectious diseases in animals by initiating qualitative and quantitative changes in the phagocytic cells of said animals. This activation occurs by the administration of a phagocytic-cell activating agent, such as immunomodulators; cytokines such as interleukins (interleukin -1, 2, 3, 4, 5, 6 and 7), interferons and colony stimulating factors; antimicrobials such as mucolytic enzymes, lysozyme, lysostaphin; complement and its components; chemotractants such as lipopolysaccharide and zymosan activated cow sera. The appropriate activation of the phagocytic cells in the animal for effective therapy requires not only an increase in the total number of cells which phagocytose cell particles, but also an increase in the number of particles phagocytosed per cell, intracellular killing. Thus, the present invention also relates to a method for measuring the efficiency of phagocytic-activating agents to predict and monitor appropriate therapy.</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; TESTING</subject><creationdate>1991</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19910102&amp;DB=EPODOC&amp;CC=EP&amp;NR=0405315A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19910102&amp;DB=EPODOC&amp;CC=EP&amp;NR=0405315A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DALEY, MICHAEL JOSEPH</creatorcontrib><title>Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows</title><description>The present invention relates to methods for treating infectious diseases in animals by initiating qualitative and quantitative changes in the phagocytic cells of said animals. This activation occurs by the administration of a phagocytic-cell activating agent, such as immunomodulators; cytokines such as interleukins (interleukin -1, 2, 3, 4, 5, 6 and 7), interferons and colony stimulating factors; antimicrobials such as mucolytic enzymes, lysozyme, lysostaphin; complement and its components; chemotractants such as lipopolysaccharide and zymosan activated cow sera. The appropriate activation of the phagocytic cells in the animal for effective therapy requires not only an increase in the total number of cells which phagocytose cell particles, but also an increase in the number of particles phagocytosed per cell, intracellular killing. Thus, the present invention also relates to a method for measuring the efficiency of phagocytic-activating agents to predict and monitor appropriate therapy.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1991</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjTEOgkAQRWksjHqHuQAJgjR2xmA0oSBRazMZZ2ET2Nmwi4YreGpX5QBW_xfv_T-PXlfHIAoQbIO10Og5RvL6gV6bGrBm42ELZXUG6eFUximoUHzD0KEZVGCHflro-K4Ju4_xZXr-jTiPthlbISEaHGAQQmijOByJCQ1Inm4ZzRS2jldTLiI4FJf9MWYrN3YWiQ37W1ElmyTP1vkuzf5A3qxfSxo</recordid><startdate>19910102</startdate><enddate>19910102</enddate><creator>DALEY, MICHAEL JOSEPH</creator><scope>EVB</scope></search><sort><creationdate>19910102</creationdate><title>Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows</title><author>DALEY, MICHAEL JOSEPH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP0405315A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>1991</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>DALEY, MICHAEL JOSEPH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DALEY, MICHAEL JOSEPH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows</title><date>1991-01-02</date><risdate>1991</risdate><abstract>The present invention relates to methods for treating infectious diseases in animals by initiating qualitative and quantitative changes in the phagocytic cells of said animals. This activation occurs by the administration of a phagocytic-cell activating agent, such as immunomodulators; cytokines such as interleukins (interleukin -1, 2, 3, 4, 5, 6 and 7), interferons and colony stimulating factors; antimicrobials such as mucolytic enzymes, lysozyme, lysostaphin; complement and its components; chemotractants such as lipopolysaccharide and zymosan activated cow sera. The appropriate activation of the phagocytic cells in the animal for effective therapy requires not only an increase in the total number of cells which phagocytose cell particles, but also an increase in the number of particles phagocytosed per cell, intracellular killing. Thus, the present invention also relates to a method for measuring the efficiency of phagocytic-activating agents to predict and monitor appropriate therapy.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP0405315A2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
title Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A49%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DALEY,%20MICHAEL%20JOSEPH&rft.date=1991-01-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP0405315A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true